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Abstract
Background: Cdc42 and Rac1, members of the Rho family of small GTPases, play critical roles in actin cytoskeleton
regulation. We have shown previously that Rac1 is involved in regulation of platelet secretion and aggregation. However,
the role of Cdc42 in platelet activation remains controversial. This study was undertaken to better understand the role of
Cdc42 in platelet activation.
Methodology/Principal Findings: We utilized the Mx-cre;Cdc42
lox/lox inducible mice with transient Cdc42 deletion to
investigate the involvement of Cdc42 in platelet function. The Cdc42-deficient mice exhibited a significantly reduced
platelet count than the matching Cdc42
+/+ mice. Platelets isolated from Cdc42
2/2, as compared to Cdc42
+/+, mice exhibited
(a) diminished phosphorylation of PAK1/2, an effector molecule of Cdc42, (b) inhibition of filopodia formation on
immobilized CRP or fibrinogen, (c) inhibition of CRP- or thrombin-induced secretion of ATP and release of P-selectin, (d)
inhibition of CRP, collagen or thrombin induced platelet aggregation, and (e) minimal phosphorylation of Akt upon
stimulation with CRP or thrombin. The bleeding times were significantly prolonged in Cdc42
2/2 mice compared with
Cdc42
+/+ mice.
Conclusion/Significance: Our data demonstrate that Cdc42 is required for platelet filopodia formation, secretion and
aggregation and therefore plays a critical role in platelet mediated hemostasis and thrombosis.
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Introduction
Cdc42, a member of the Rho family of small GTPases, has been
implicated in regulation of numerous cellular processes including
organization of actin cytoskeleton, cell-cell and cell-extracellular
matrix adhesion, and spreading [1–6]. Although Cdc42 was
reported to be present in platelets more than twenty-two years ago
[7], a better understanding of its role in regulation of platelet
activation has remained elusive. Binding of agonists such as
thrombin-receptor activated peptide (TRAP) to its receptors on
platelets has been shown to induce integrin aIIbb3 mediated
translocation of Cdc42 to the cytoskeleton in a reversible manner
[8]. Out-side in signaling in platelets initiated by binding of von
Willebrand factor (vWf) to platelet GP Ib-IX has been reported to
induce activation of Cdc42 that involves interaction of GP 1b-IX
with 14-3-3f [9]. Moreover, it has been shown that thrombin
induced activation of platelets results in accumulation of GTP-
bound active form of Cdc42 [10] and that Cdc42 dependent
activation of p21-activated kinase (PAK) induces platelet lamelli-
podia formation [11].
To date, the role of Cdc42 in platelet filopodia formation,
secretion and aggregation remains unclear. One report has
suggested that pharmacologic inhibition of Cdc42 inhibits platelet
adhesion to immobilized collagen as well as aggregation induced
by collagen but does not inhibit adhesion of platelets to CRP or
fibrinogen or platelet aggregation induced by CRP or thrombin
[12]. Another report has shown that constitutive megakaryocyte/
platelet-specific deletion of Cdc42 in mice results in increased
secretion and aggregation responses to diverse agonists as well as
increased platelet aggregate formation on collagen under flow
[13]. The contradictory data and conclusions presented in these
two reports fail to clarify the role of Cdc42 in platelet activation.
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22117To more clearly define the role of Cdc42 in platelet activation we
have utilized Cdc42 null platelets from an inducible Cdc42
knockout mouse model obtained by a different gene targeting
strategy [14]. Mouse embryonic fibroblasts and T-cells, as well as
other lineages, from this mouse strain have been shown to be
readily rescued in various phenotypes from filopodia induction,
directional migration, proliferation, and differentiation to survival
by reconstitution with WT Cdc42 [15,16]. Here we report that the
mice with inducible deletion of Cdc42 in blood cells exhibit not
only thrombocytopenia and prolonged bleeding times but also
display severe defects in filopodia formation and aggregation
possibly due to inhibition of secretion and blockade of Akt
phosphorylation regardless of the nature of agonists employed.
These consistent phenotypes and mechanisms establish a bona fide
physiological role of Cdc42 in the regulation of platelet activation
induced by agonists that activate platelets by GPVI-dependent as
well as GPVI-independent signaling.
Materials and Methods
Materials
Chemicals and reagents were purchased either from Sigma-
Aldrich or from specifically noted sources. Collagen was obtained
from Chrono-Log Corporation. Anti-Cdc42 antibody was pur-
chased from BD Biosciences and anti-PAK and p-PAK1/2, Akt
and p-Akt antibodies were obtained from Cell Signaling. Collagen
related peptide (CRP) was synthesized as reported earlier [17].
Methods
Mouse maintenance, blood collection and preparation of
washed mice platelet suspensions. All experiments using
mice were performed according to the protocols approved by the
Institutional Animal Care and Use Committees at the Children’s
Hospital Research Foundation (IACUC Protocol#8D06052),
Cincinnati, Ohio and at Ohio University (IACUC Protocol#
H08-12) Athens, Ohio. The Mx-cre, Mx-cre;Cdc42
loxP/loxP mice
were generated previously [14,18]. Inducible deletion of Cdc42
GTPase from the platelets of the mice was achieved by 4–5 intra-
peritoneal injections of poly (I:C) as described [14]. Platelets
from the Mx-cre;Cdc42
WT/WT mice given 4–5 intra-peritoneal
injections of poly (I:C) were used as control samples. Protocol for
drawing blood and washing murine platelets is essentially the same
as we described earlier [19]. Blood was drawn by cardiac puncture
from anesthetized wild type (WT) and Cdc42 deficient mice into a
syringe containing 160 ml of ACD (2.5% trisodium citrate, 2%
dextrose, 1.5% citric acid) and transferred into tubes containing
500 ml of HEPES-buffered Tyrode’s solution. Platelets were
isolated by centrifugation at 90g for 10 minutes, immediately
after adding 5 mM EDTA [19–21]. The remainder of blood was
diluted to 1.5 ml with HEPES-buffered Tyrode’s solution, pH 6.5
and centrifuged at 90g for 10 minutes to recover additional
platelets. Platelets were washed three times, in the presence of
apyrase (0.4 U/ml), an enzyme that hydrolyzes ADP, and 2.0%
EGTA, with HEPES-buffered Tyrode’s solution, pH 6.5 and
finally resuspended in HEPES-buffered Tyrode’s solution without
calcium, pH 7.4 and counted in Hemavet 950FS (Drew Scientific,
CT, USA). The platelet count was adjusted to 2.5610
8 per ml for
aggregation studies.
Platelet actin structures on fibrinogen and collagen-
related peptide. Glass cover slips were coated with fibrinogen
or collagen-related peptide overnight at 4uC. Non-specific binding
was blocked by incubating cover slips with bovine serum albumin
(BSA, 1%) in phosphate-buffered saline (PBS) at 37uC. Cover slips
were rinsed with Tyrode’s-HEPES buffer after removing BSA.
Washed platelets from Cdc42
+/+ and Cdc42
2/2 mice were
layered over cover slips and incubated at 37uC for time periods
shown in figure legends. The cover slips were rinsed with PBS to
remove free platelets. Platelets on cover slips were then fixed with
4% paraformaldehyde for ten minutes, rinsed with PBS twice and
permeabilized with 0.1% Triton X-100 for 60 seconds. After two
rinses with PBS platelets were stained with Alexa 594-phalloidin to
visualize F-actin. Matching immuno-fluorescence and differential
interference contrast (DIC) images were taken with a Nikon E-600
microscope using a Plan Apo 60x/1.4 oil objective. Digital photos
were recorded with a Spot camera using Spot Advanced software
version 4.7 and Photoshop was used to auto adjust brightness and
contrast. Platelet spreading was quantified using the Image J
software (http://rsbweb.nih.gov/ij).
Assessment of P-selectin expression, secretion of ATP and
platelet aggregation. P-selectin release was assessed as
described earlier [19]. The PRP was incubated with 1 mM
aspirin at 37uC for 30 minutes and then platelets were isolated by
centrifugation, washed twice and finally resuspended in HEPES-
buffered Tyrode’s solution without calcium, pH 7.4 containing
0.2% bovine serum albumin and apyrase (0.1 U/ml). Washed
platelets (1–1.5610
6) were incubated with 10 ml of FITC-
conjugated anti-CD62P (P-selectin) antibody solution for 30
minutes at 37uC without stirring. Expression of P-selectin on
platelet surface was quantified by flow cytometry (FACSCalibur,
Becton-Dickinson) and the Cellquest software program [22].
Secretion of ATP from the dense granules was assessed by a
luminescence method using a luciferin/luciferase kit from Chrono-
Log Corporation (Havertown, PA) [19]. The luciferin/luciferase
reagent was added to platelets one minute prior to addition of
CRP. Platelet aggregation was monitored as reported earlier
[19,20] using a Lumi-Aggregometer at 37uC and a stirring speed
of 900 rpm. Washed Cdc42
+/+ and Cdc42
2/2 platelets were
stimulated with CRP, collagen or thrombin and aggregation was
recorded for 4 minutes.
Phosphorylation of PAK1/2 and Akt. Washed murine
platelets were stimulated with thrombin or CRP for a specified
time period. The reactions were terminated by addition of 56
sample buffer. Western blotting of PAK1/2, p-PAK1/2, Akt, and
p-Akt, and b-actin were done as reported earlier [14].
Tail bleeding time measurement. Tail bleeding time
measurements were performed as described earlier [19]. Mice
were anesthetized with and kept under a constant flow of 2.5%
isoflurane and 0.35% of oxygen. The tip of the tail at 1.5 mm
diameter was cut and immediately immersed in saline at 37uC.
The bleeding time was defined as the time needed for the cessation
of visible blood stream for one minute [23]. Monitoring of the
bleeding times was stopped at 15 minutes by cauterizing the tails
to prevent excessive loss of blood.
Statistical analysis. Data are expressed as means 6 SD or
SEM (as described in figure legends). Statistical significance
between the bleeding times of the Cdc42
+/+ and Cdc42
2/2
mice was assessed by student’s t-test. The p values of less than 0.05
are considered statistically significant.
Results
Inducible deletion of Cdc42 from bone marrow results in
thrombocytopenia
An interferon-inducible method was used to generate condi-
tional knockout mice lacking Cdc42 in hematopoietic cells
including platelets, in the Mx-cre:Cdc42
loxP/LoxP mice [14]. Loss
of Cdc42 in the platelets isolated from the Mx-cre:Cdc42
loxP/LoxP
mice 5–10 days after the poly(I:C) treatment was assessed by
Role of Cdc42 GTPase in Platelet Activation
PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e22117Western blotting. As shown in Fig. 1A, Cdc42 GTPase is
expressed in platelets from the Cdc42
+/+ but not in platelets from
Cdc42
2/2 mice. We investigated the possibility that inducible
deletion of Cdc42 may have affected expression of Rac1 or RhoA.
Blots in Fig. 1A demonstrate that expression of neither Rac1 nor
RhoA is altered by deletion of Cdc42. The platelet count in
Cdc42
2/2 mice was significantly lower than that in the Cdc42
+/+
mice (Fig. 1B). Platelet volume (Means 6 SD) was increased in
Cdc42
2/2 mice (5.4560.22 fl, n=11) as compared to Cdc42
+/+
mice (4.9260.24 fl, n=12). Our findings of thrombocytopenia
and an increase in platelet volume in Cdc42-deficient mice are in
agreement with a recent report of thrombocytopenia and an
increase in the size of platelets in mice constitutively lacking Cdc42
in megakaryocytes and platelets [13], and confirm that Cdc42 is
involved in platelet production.
Activation of PAK1/2 is significantly diminished in Cd42
2/2
platelets
Platelet agonists such as thrombin, TRAP and collagen all have
been shown to induce activation of Rac1 as well as Cdc42
[10,11,19]. Activation of Rac1 or Cdc42 GTPase leads to
phosphorylation of PAK1/2, the putative effector molecule, in
platelets and other cell types [11,24,25]. We have shown
previously that genetic or pharmacologic targeting of Rac1
prevents phosphorylation of PAK1/2 [19]. To examine if
PAK1/2 activity is also regulated by Cdc42 in platelets, washed
platelets from the Cdc42
+/+ and Cdc42
2/2 mice were stimulated
with collagen-related peptide (CRP) or thrombin for two minutes
and phosphorylation of PAK1/2 was assessed by Western blotting.
As shown in Fig. 1C, CRP- or thrombin-induced phosphorylation
of PAK1/2 in Cdc42
2/2, as compared to Cdc42
+/+, platelets is
diminished by 85% and 75% respectively. These findings that
inducible deletion of Cdc42 prevents agonist induced signaling
downstream of Cdc42 further validate the use of this Cdc42-
deficient mouse model for investigating the role of Cdc42 in
platelet activation.
Cdc42
2/2 platelets fail to form filopodia or lamellipodia
on fibrinogen or CRP
Cdc42 is known to regulate actin polymerization and filopodia
formation, as well as spreading, on cellular and extra-cellular
matrices in several cell types [26,27]. We investigated the effect of
deficiency of Cdc42 on platelet actin structures on immobilized
fibrinogen or CRP to determine the role of Cdc42 in integrin
Figure 1. Gene targeting of Cdc42 induced thrombocytopenia and blocked signaling downstream of Cdc42. A, Expression of Cdc42,
Rac1 and RhoA in platelet lysates from the wild type and genetically targeted mice was probed by Western blotting of Cdc42, Rac1 and RhoA.
Platelets from Cdc42 gene targeted mice as compared to the poly (I:C) treated matching wild type mice showed a complete lack of Cdc42 GTPase.
The expression of Rac1 and RhoA was not altered in Cdc42
2/2 platelets. b-actin expression was used as a loading control. B, Platelet counts (Mean 6
SEM) in the Cdc42
2/2 mice (n=11) were significantly lower (p,0.05) than the platelet counts in the Cdc42
+/+ mice (n=12). C, CRP (0.2 mg/ml) or
thrombin (0.1 U/ml) induced phosphorylation of PAK1/2 is inhibited in the Cdc42
2/2 mice platelets as compared to the platelets from Cdc42
+/+ mice.
Phosphorylation of PAK1/2 was analyzed as described in the methods section.
doi:10.1371/journal.pone.0022117.g001
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respectively. Aspirin treated washed Cdc42
+/+ and Cdc42
2/2
mice platelets were layered over immobilized fibrinogen or CRP in
the presence of apyrase and morphological changes were assessed
by immuno-fluorescence and DIC microscopy. Platelets from
Cdc42
2/2 mice, as compared to Cdc42
+/+ mice, failed to form
filopodia or lamellipodia on immobilized CRP (Fig. 2). The
micrographs in Fig. 3 show that Cdc42
2/2 platelets failed to form
filopodia on immobilized fibrinogen. The spreading of Cdc42
2/2
platelets on immobilized CRP (21.361.3 mm
2) or fibrinogen
(11.360.4 mm
2) was significantly diminished as compared to the
Cdc42
+/+ platelets spreading on CRP (52.761.9 mm
2) or fibrin-
ogen (17.560.5 mm
2) respectively (Fig. 4).
The inability of Cdc42
2/2 platelets to form filopodia or lamelli-
podia either on fibrinogen or CRP suggests that Cdc42 plays an
important role not only in integrin aIIbb3 mediated out-side in
signaling but also GPVI mediated inside-out signaling that promotes
binding of collagen to integrina2b1.Failure of Cdc42
2/2 plateletsto
form filopodia on CRP, a GPVI specific agonist, further supports a
critical role for Cdc42 in GPVI mediated signaling in platelet
activation.
Gene targeting of Cdc42 inhibits secretion from the
alpha and the dense granules
Rac1 and Cdc42 have been implicated in regulating exocytosis
[28–33]. Cdc42 has been shown to be involved in second phase of
insulin granule exocytosis in pancreatic islet beta cells [29] as well
as glucagon-like peptide-1 secretion in the intestinal endocrine L
cell [34]. We have observed that Rac1 is involved in secretion
from platelet granules [19]. We investigated the role of Cdc42 in
secretion by quantifying release of P-selectin from the a-granules
and secretion of ATP from the dense granules in platelets from
Cdc42
+/+ and Cdc42
2/2 mice. The data in Fig. 5 show that
thrombin or CRP induced release of P-selectin and secretion of
ATP in Cdc42
2/2 platelets, as compared to Cdc42
+/+ platelets, is
diminished. These findings implicate Cdc42 as a positive regulator
of platelet secretion.
Platelet aggregation induced by thrombin, CRP or
collagen is inhibited in Cdc42
2/2 platelets
In platelets, agonist-receptor mediated inside-out signaling
induces exposure of integrin aIIbb3. Binding of fibrinogen to
aIIbb3 culminates in platelet aggregation. Agonist induced
Figure 2. Inducible genetic targeting of Cdc42 inhibited filopodia and lamellipodia formation on immobilized collagen-related
peptide. Washed platelets from Cdc42
+/+ (A) and Cdc42
2/2 (B) mice were layered over cover slips coated with CRP (0.5 mg/ml) for 20 minutes. The
cover slips were washed and adherent platelets were processed for DIC (top panel) and immuno-fluorescence (bottom panel) microscopy as detailed
in the methods section. Platelets from Cdc42
2/2 mice failed to form filopodia or lamellipodia on CRP.
doi:10.1371/journal.pone.0022117.g002
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Cdc42
+/+ (A) and Cdc42
2/2 (B) mice were layered over cover slips coated with fibrinogen (3.0 mg/ml) for 20 minutes. The DIC (top panel) and
immuno-fluorescence (bottom panel) images show that platelets from Cdc42
2/2 mice failed to form filopodia on immobilized fibrinogen.
doi:10.1371/journal.pone.0022117.g003
Figure 4. Inducible genetic targeting of Cdc42 inhibited
platelet spreading on immobilized CRP and fibrinogen.
Spreading of washed platelets from Cdc42
+/+ and Cdc42
2/2 mice on
CRP or fibrinogen was quantified using Image J software (http://rsbweb.
nih.gov/ij). Each bar represents mean surface are 6 SEM of 100
platelets. The spreading of Cdc42
2/2 platelets on immobilized CRP or
fibrinogen was significantly (p,0.01) diminished as compared to the
Cdc42
+/+ platelets.
doi:10.1371/journal.pone.0022117.g004
Figure 5. Genetic targeting of Cdc42 inhibited release of
p-selectin from a-granules and secretion of ATP from dense
granules. A, Thrombin (0.2 U/ml) induced expression of P-selectin and
B, CRP (0.2 mg/ml) induced secretion of ATP is inhibited in platelets from
Cdc42
2/2 mice compared with the platelets from Cdc42
+/+ mice. Bar
graphs are the means 6 SD (n=3).
doi:10.1371/journal.pone.0022117.g005
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pivotal role in aggregation induced by diverse agonists [35]. We
investigated the possibility that deficiency of Cdc42 may also
inhibit platelet aggregation in part due to diminished secretion.
Threshold concentration of thrombin (0.05 U/ml) induced
nominal aggregation in Cdc42
+/+ platelets without inducing any
discernable aggregation response in Cdc42
2/2 platelets (Fig. 6).
Increasing concentrations of thrombin (0.1–0.2 U/ml) induced
maximal aggregation in Cdc42
+/+ platelets. Aggregation responses
at all thrombin concentrations were diminished in Cdc42
2/2
platelets (Fig. 6). It is important to note that in Cdc42
2/2 platelets
only primary or reversible aggregation response was observed with
increasing concentrations of thrombin. The lack of secondary
aggregation response in Cdc42
2/2 platelets that depends on
secretion of ADP suggests that inhibition of secretion due to
Cdc42-deficiency is at least partially responsible for the diminished
aggregation.
Addition of CRP (0.2–0.4 mg/ml), a GPVI specific agonist, to
Cdc42
+/+ platelets induced a typical aggregation responses but
only induced nominal aggregation response in Cdc42
2/2 platelets
(Fig. 6). Similarly addition of collagen (2–3 mg/ml) to Cdc42
+/+
platelets induced a typical aggregation pattern. In contrast,
platelets from Cdc42
2/2 platelets failed to undergo aggregation
upon stimulation with collagen (Fig. 6). The diminished platelet
aggregation responses to thrombin, CRP or collagen seen in
Cdc42
2/2 platelets indicate that Cdc42 plays an important role in
aggregation induced by GPVI- and non-GPVI mediated platelet
activation.
Agonist-induced activation of Akt is diminished in Cdc42-
deficient platelets
Diverse platelet agonists induce phosphorylation of Akt [36–41].
Phosphorylation of Akt has been linked to secondary aggregation
[42]. Secreted ADP induces Akt phosphorylation via Gai mediated
signaling [39]. However, phosphorylation of Akt induced by
convulxin, a GPVI specific agonist, is mediated, in part, by
secreted ADP and in part by activation of PI3Kb [43]. We
investigated the role of Cdc42 in thrombin and CRP induced
activation of Akt. The data in Fig. 7 show that CRP or thrombin
induced phosphorylation of Akt is inhibited in Cdc42
2/2 platelets.
These findings suggest that Cdc42 is critical in Akt phosphory-
lation mediated by diverse signaling mechanisms and consequent
platelet aggregation.
Cdc42-deficient mice exhibit prolonged tail bleeding
times
Platelet aggregation at the site of injury constitutes the primary
hemostatic response that ultimately leads to arrest of bleeding. A
defective or diminished aggregation may slow or prevent
hemostasis. We hypothesized that diminished aggregation in
Cdc42-deficient mice may lead to a delayed hemostasis. To test
this possibility we performed tail bleeding time assay in Cdc42
+/+
and Cdc42
2/2 mice as described earlier [19]. The data in Fig. 8
show that Cdc42
2/2 mice, as compared to Cdc42
+/+ mice, had a
significantly prolonged bleeding time. The prolonged tail bleeding
times taken together with diminished aggregation responses in
Figure 6. Deficiency of Cdc42 inhibited platelet aggregation
induced by collagen, CRP or thrombin. Washed platelets from
Cdc42
+/+ and Cdc42
2/2 were stimulated by addition of CRP (A),
collagen (B) or thrombin (C) and aggregation was recorded using a
Lumi-Aggregometer at 37uC and a stirring speed of 900 rpm. Platelets
from Cdc42
2/2 mice compared with the platelets from the Cdc42
+/+
mice exhibited diminished aggregation induced by all three agonists.
The aggregation tracings are representative of three experiments.
doi:10.1371/journal.pone.0022117.g006
Figure 7. Agonist-induced phosphorylation of Akt is reduced
in Cdc42
2/2 platelets. Washed platelets from Cdc42
+/+ and Cdc42
2/2
mice were incubated with CRP (0.2 mg/ml) or thrombin (0.1 U/ml) for
5 minutes at 37uC with constant stirring in a Chrono-Log aggreg-
ometer. The reactions were terminated by adding 56 sample buffer,
processed for Western blotting and probed for Akt, p-Akt and b-actin as
detailed in methods.
doi:10.1371/journal.pone.0022117.g007
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2/2 mice strongly suggest that Cdc42 regulates platelet
dependent primary hemostasis.
Discussion
Cdc42 is a member of the Rho family of small GTPases and has
been known to regulate actin organization and associated
morphological changes such as filopodia formation in a variety
of cell types. However, its role in platelet activation, particularly
filopodia formation, granular secretion and aggregation, is
controversial at this time due to recent contradictory reports
[12,13]. This study was undertaken to more clearly define the role
of Cdc42 in regulation of platelet activation using an inducible
Cdc42 knockout mouse model. The data in Fig. 1A show that gene
targeting of Cdc42 resulted in a lack of expression of Cdc42 but
did not affect expression of related Rac1 and RhoA. Our findings
that inducible gene targeting of Cdc42 results in a significant
thrombocytopenia (Fig. 1) and prolonged tail bleeding times in
Cdc42-deficient mice (Fig. 8) demonstrate that Cdc42 is essential
for normal platelet function. These observations are in agreement
with a recent report that megakaryocyte/platelet specific consti-
tutive deletion of Cdc42 results in thrombocytopenia as well as
prolonged tail bleeding times [13].
We have previously reported that deletion of Cdc42 leads to
hematopoietic stem/progenitor cell defects in differentiation, cell
cycle progression, and homing/lodging in the bone marrow
[14,44]. Thus, the observed partial reduction in platelet
production in Cdc42 deficient mice may be due to early
progenitor defects as well as defects in megakaryocyte differenti-
ation. The mechanisms by which Cdc42 regulates platelet
production remain unclear at this time. The interferon inducible
deletion of Cdc42 in Mx-cre;Cdc42
lox/lox mice affects all blood
lineages including the stem/early progenitor compartments and
therefore makes this particular mouse model unsuitable for
studying the developmental mechanism of a terminal lineage like
platelet.
Wiskott-Aldridge Syndrome (WAS) patients exhibit thrombo-
cytopenia [45]. Since Wiskott-Aldridge Syndrome Protein (WASP)
is regulated by Cdc42, deficiency of Cdc42 may be involved in
thrombocytopenia. However, Cdc42 engages multiple effector
pathways including PAK, WASP, IQGAP, Par6 [16], making it
difficult to sort out the specific contribution of WASP to the
diminished platelet number in Cdc42-deficient mice. Technical
difficulties in reintroducing Cdc42 mutants (e.g. defective in
WASP binding) to platelets pose another challenge for demon-
strating a causal relationship between Cdc42 deficiency, defective
WASP activation and thrombocytopenia. More recently WASP
has been shown to play an important role in regulation of integrin
aIIbb3 mediated platelet activation [45] and it is possible that this
pathway is involved in Cdc42 mediated aIIbb3 regulation.
The p-21activated kinases (Paks) are known effector molecules of
Cdc42 and have been linked with actin polymerization and
lamellipodia formation. The Paks have been shown to be
phosphorylated in platelets by thrombin, TRAP as well as
convulxin, a GPVI agonist [11,46]. Our finding that CRP, a GPVI
specific agonist, as well as thrombin induced phosphorylation of
PAK1/2 is inhibited in Cdc42-deficient platelets (Fig. 1) confirms
not only deletion of Cdc42 in the gene targeted mice but also
demonstrates that signaling downstream of Cdc42 has been
effectively blocked in Cdc42
2/2 platelets. This is a first report to
show that the Cdc42 is involved in GPVI-specific signaling leading
to phosphorylation of PAK1/2 in murine platelets. We have
reported earlier that gene targeting or pharmacologic inhibition of
Rac1 also inhibits activation of PAK1/2 [19]. Thus, PAK1/2
appears to be subjected to a dual regulation by Cdc42 and Rac1 in
platelets. This suggests that Cdc42/Rac1 either function sequen-
tially or in parallel on this ‘‘shared’’ effector. How PAK1/2 is
regulated by both Cdc42 and Rac1 in platelets is not clear at this
point. One possibility is that the regulation of PAK1/2 by Cdc42/
Rac1 may involve heterodimerization of PAK1/2 and binding of
the PAK1/2 dimer to Cdc42/Rac1 simultaneously. Alternatively,
Cdc42 and Rac1 may act sequentially in a signaling cascade leading
to PAK regulation. Investigations of these hypotheses to resolve the
functional relationship between Cdc42 and Rac1 would require
multiple gene targeting and transgenic approaches as most standard
gene transfer techniques are not applicable in platelets.
Agonists that induce platelet activation also activate Cdc42 [10]
and active Cdc42 can initiate platelet actin cytoskeleton reorgani-
zation [9] leading to lamellipodia [11] and filopodia formation [47].
Ligand density has been shown to affect integrin aIIbb3-mediated
platelet signaling and spreading [48] and increasing agonist
concentrations, at least partially, reverse the diminished aggregation
responses observed in Cdc42 deficient platelets (Fig. 6). We therefore
utilized lower concentrations of immobilized fibrinogen (3 mg/ml)
and CRP ((0.5 mg/ml) to investigate the role of Cdc42 in platelet
morphological changes. Our findings that Cdc42
2/2 platelets failed
toformfilopodiaorlamellipodiaandexhibited diminishedspreading
on immobilized fibrinogen or CRP (Figs. 2, 3, and 4) clearly
demonstrate that Cdc42 is involved in reorganization of actin
cytoskeleton. The inability of Cdc42
2/2 platelets to form filopodia
on immobilized fibrinogen clearly demonstrate that Cdc42 is
essential for integrin aIIbb3-depedent outside-in signaling involved
in reorganization of actin cytoskeleton. The findings that murine
platelets were able to form filopodia on immobilized CRP show that
GPVIisinvolved infilopodia formation. Moreover,ourobservations
that Cdc42
2/2 platelets were unable to form filopodia on CRP
clearly demonstrate that Cdc42 is critical for the GPVI mediated
actin reorganization. Using secramine A, a non-specific inhibitor,
PulaandPoole [12] havesuggestedthatinhibitionofCdc42partially
blocks spreading of platelets on collagen, CRP and fibrinogen.
However, our findings disagree with a recent report showing that
megakaryocytes/platelets specific deletion of Cdc42 had no effect on
filopodia formation on immobilized fibrinogen or CRP [13]. The
reason for this discrepancy is not clear at this time. These
investigators have also suggested that Cdc42-deficient platelets
exhibit specific defect in GPIb-specific signal as evidenced by the
reduced extension of filopodia on immobilized vWf. However, they
used a significantly lower concentration of vWf (10 mg/ml) as
Figure 8. Deficiency of Cdc42 prolonged tail bleeding time. The
tail bleeding times were assessed in Cdc42
+/+ (n=8) and Cdc42
2/2
(n=8) mice as detailed in methods. Bar graphs are the means 6 SEM of
the bleeding times. Cdc42-deficient, as compared to Cdc42
+/+, mice
exhibited significantly prolonged (p,0.05) bleeding times.
doi:10.1371/journal.pone.0022117.g008
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is possible that platelets from their Cdc42
2/2 mice would have
exhibited defective filopodia formation if significantly lower
concentrations of fibrinogen or CRP were used. Another possible
explanation for the discrepancy may be that constitutive, but not
transient inducible deletion of Cdc42, in megakaryocytes/platelets
results in compensatory expression and/or activation of Cdc42-
related Rho GTPases such as TC10, TCL or Rif. Such differences
betweenthetwo knockoutsystemsaredifficulttoconfirmatthistime
due to the lack of specific antibodies and probes.
Cdc42 has been shown to be critical in exocytosis in a number
of cell types [29,34]. Our findings that platelets from mice with
inducible deletion of Cdc42 exhibit diminished secretion from
platelet granules (Fig. 5) suggest that Cdc42 plays a critical role in
platelet secretory responses. However, Pleines et al. [13] have
shown that platelets from mice with constitutive deletion of Cdc42
exhibit increased secretory responses. There is no apparent
mechanistic explanation for the decreased secretion observed by
us (Fig. 5) and the enhanced secretion reported by them. We
quantified secretion in washed murine platelets using a luciferin/
luciferase chemi-luminescence method. They quantified ATP in
supernatants of PRP from heparinized blood after terminating the
reactions with EDTA and fixing platelets with formaldehyde. The
differences in methodology for assessing secretion, in addition to
above discussed genetic models, may account for the differences in
these observations.
The functional consequence of platelet activation reactions is
aggregation or bridging of platelets that occurs due to binding of
fibrinogen to integrin aIIbb3 on the adjoining platelets. Diverse
agonists bind to their specific receptors on platelets and initiate
signaling cascades leading to the so-called inside-out signaling that
culminates in secretion from platelet granules and a many-fold
increase in exposure of integrin aIIbb3 on platelet surface and
consequently a much greater aggregation response. If secretion
from platelet granules is essential for maximal, or the so-called
irreversible, platelet aggregation response then diminished secretion
responses observed in Cdc42
2/2 platelets (Fig. 5) would result in
diminished platelet aggregation response. Indeed our findings that
platelet aggregation responses induced by thrombin, collagen or
CRPareeitherminimalordiminishedinCdc42
2/2platelets(Fig.6)
suggest that diminished secretion, at least in part, is responsible for
impaired aggregation responses in Cdc42
2/2 platelets. Impaired
aggregationresponsesinduced bydiverse agonistssuch asthrombin,
collagen or CRP imply that a common rather than an agonist-
specific signaling mechanism is responsible for defective platelet
aggregation in Cdc42
2/2 mice. Agonist induced activation of Akt is
one such common signaling mechanism. Secondary or irreversible
platelet aggregation has been linked to phosphorylation of Akt [42].
Secreted ADP, regardless of the nature of the agonist employed,
induces phosphorylationof Akt via activation of Gai [39] and GPVI
specific agonists such as convulxin induce phosphorylation of Akt in
part due to secreted ADP and in part due to activation of PI3Kb
[43]. Our findings that CRP, a GPVI specific agonist, and
thrombin, that activates murine platelets via PAR3/4 receptors,
both induced minimal or only reversible aggregation (Fig. 6) as well
as induced only nominal phosphorylation of Akt in Cdc42
2/2,a s
compared to the Cd42
+/+, platelets (Fig. 7) suggest that deficiency of
Cdc42 results in defective platelet aggregation, at least in part, due
to inhibition of phosphorylation of Akt.
Our observation that Cdc42
2/2 platelets exhibit impaired
platelet aggregation in response to CRP, collagen or thrombin
differ from the report showing that platelets from constitutively
deleted Cdc42 mice exhibit increased aggregation responses upon
stimulation with collagen or CRP and a similar aggregation
response upon stimulation with thrombin [13]. These investigators
have suggested that increased aggregation induced by collagen and
CRP is due to enhanced secretion from platelet granules. There is
no obvious explanation for the different observations made by
them and us. Again, methodological differences may be attributed
to the different findings. However, our data (Fig. 8) and their
observation of a prolonged bleeding time in Cdc42
2/2 mice are
hard to reconcile with enhanced secretion/aggregation responses
in Cdc42
2/2 platelets.
Pula and Poole [12] have reported that secramine A blocks
collagen but not CRP induced platelet aggregation. However, the
non-selective nature of the inhibitor as well as the excessively high
concentration of collagen (30 mg/ml) and CRP (5 mg/ml) used in
this study make it difficult to compare their data with our data in
Cdc42
2/2 platelets where we used 10-times lower concentration
of collagen and CRP. It is possible that secramine A might have
inhibited normal i.e. typical aggregation response induced by a
lower concentration of CRP.
Platelet aggregation at the site of injury forms the primary
hemostatic plug leading to an arrest of bleeding. Standardized
bleeding times are considered a measurement of platelets
functional integrity. Our findings of prolonged tail bleeding times
in Cdc42
2/2 mice (Fig. 8), consistent with observation by Pleines
et al. [13], along with the observed impaired secretion and
aggregation in Cdc42
2/2 platelets (Figs. 5,6) clearly demonstrate
that Cdc42 plays an essential role in regulation of platelet function
and thus is critical for platelet mediated primary hemostasis.
In summary, our data implicate Cdc42 not only in reorgani-
zation of actin cytoskeleton including filopodia formation induced
by fibrinogen, an integrin aIIbb3-dependent and CRP, a GPVI-
dependent, pathway, but also in platelet aggregation. Regulation
of granular secretion and Akt phosphorylation by Cdc42 appears
to determine, at least in part, the extent of platelet aggregation
induced by agonists that employ the GPVI and non-GPVI
signaling pathways.
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